Melanoma DNA vaccine - Oxxon Therapeutics
Alternative Names: Hi-8 MEL; MEL1 immunotherapy - Oxxon; pSG2.MEL3/MVA.MEL3Latest Information Update: 15 Sep 2015
At a glance
- Originator Oxxon Therapeutics
- Developer Oxford BioMedica
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 15 Sep 2015 No recent reports on development identified - Phase-II for Malignant melanoma in Germany and United Kingdom (unspecified route)
- 05 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been added to the Cancer therapeutic trials section
- 16 May 2005 Phase-II clinical trials in Malignant melanoma in Germany (unspecified route)